Press Release

For Immediate Distribution

SUNWAY HEALTHCARE ACHIEVES STRONG EARNINGS MOMENTUM IN Q3 AS REVENUE RISES 24% AND NET PROFIT GROWS 59%

Higher patient volumes, stronger utilisation and improving contributions from newer hospitals lift Q3 EBITDA by 32%

---

19 November 2026, KUALA LUMPUR – Sunway Healthcare Holdings Berhad ("**SHH**" or the **"Group"**), one of Malaysia's leading integrated private healthcare providers, today announced its financial results for the third quarter and nine months ended 30 September 2026 ("**Q3FY2026**" and "**9MFY2026**", respectively).

The Group sustained its strong operating momentum in Q3FY2026, supported by broad-based growth in patient activities, higher bed utilisation and improving profitability across its hospital network. Revenue and earnings continued to strengthen, with increasing contributions from the newer hospitals and better operating leverage supporting the Group's performance through the first nine months of 2026.

Key Financial and Operating Highlights (Q3FY2026)[1]

- Total licensed beds increased 20% year-on-year ("**y-o-y**") to 1,994 beds as at 30 September 2026, including 108 additional beds licensed at Sunway Medical Centre ("**SMC**") Sunway City's newly opened Tower F (Children's Tower). With total bed capacity of 2,271 beds, the Group has a further 277 completed beds available for licensing to support future growth.
- Revenue grew 24% y-o-y to RM737.4 million (Q3FY2025: RM593.1 million), supported by sustained patient demand and higher hospital utilisation.
- Bed occupancy rate improved to 76.7% (Q3FY2025: 70.6%), reflecting stronger utilisation of the Group's operating capacity. Importantly, patient demand continued to absorb the expanded capacity, with occupancy increasing despite a 20% year-on-year increase in licensed beds. Inpatient admissions increased 21% y-o-y to 36,541, while average revenue per inpatient grew 5% y-o-y to RM12,339.
- Reported EBITDA increased 32% y-o-y to RM185.2 million (Q3FY2025: RM140.3 million), outpacing revenue growth as higher patient volumes and improving contributions from the hospital network strengthened operating leverage. Reported EBITDA margin expanded by approximately 1.4 percentage points to 25.1%.
- Excluding non-recurring costs, normalised EBITDA[2] increased 32% y-o-y to RM189.2 million (Q3FY2025: RM143.3 million), with normalised EBITDA margin improving to 25.7% (Q3FY2025: 24.2%), reflecting continued improvement in underlying operating profitability.
- Profit attributable to owners of the Company ("**PATMI**") increased 59% y-o-y to RM95.2 million (Q3FY2025: RM59.7 million), supported by stronger operating earnings and lower net finance costs, which more than offset higher depreciation and income tax expenses arising from the Group's expanded operations.

Notes: 1. The financial results for Q3FY2026 and 9MFY2026 presented herein are unaudited 2. Normalised EBITDA is a non-MFRS financial measure and is presented to provide additional insight into the Group's underlying operating performance. It is not a substitute for EBITDA or profit measures prepared under MFRS.

- Net gearing ratio improved to 9% as at 30 September 2026, compared with 42% as at 31 December 2025, following the Group's successful initial public offering, providing financial flexibility to support ongoing capacity expansion and future development initiatives.
- The sustained Q3FY2026 performance lifted 9MFY2026 revenue to RM2.00 billion, up 26% y-o-y, while reported EBITDA increased 32% to RM456.0 million. Normalised EBITDA rose 36% to RM472.2 million, with reported PATMI increasing 48% to RM206.7 million, reflecting continued earnings growth across the hospital network.

Q3FY2026 Performance Overview[1]

Revenue growth remained broad-based across the Group's hospital network, supported by increased patient activities and higher bed utilisation. The Group's flagship SMC Sunway City remained the principal revenue and earnings contributor, recording revenue growth of 15% y-o-y. Mature hospitals, comprising SMC Velocity and SMC Penang, also delivered solid performance, with combined revenue increasing 24% y-o-y, supported by higher patient volumes and resilient revenue intensity.

The Group's newer hospitals, SMC Damansara and SMC Ipoh, continued to progress along their respective ramp-up curves, with combined revenue more than doubling y-o-y. Their combined contribution to Group revenue increased to 12.2% in Q3FY2026 (Q3FY2025: 6.9%), reflecting the progressive scaling of operations and growing patient demand at both facilities.

The progressive ramp-up of SMC Damansara and SMC Ipoh continues to strengthen the Group’s earnings base. Their combined EBITDA increased to RM14.5 million in Q3FY2026, with EBITDA margin improving for the third consecutive quarter to 16.2%, reflecting stronger patient throughput and improved operating cost absorption.

Medical tourism remained an important strategic growth pillar for the Group. Foreign patient revenue increased 2.2% y-o-y to approximately RM91 million. For 9MFY2026, foreign patient revenue grew 23% y-o-y, notwithstanding ongoing geopolitical uncertainties and evolving regional travel patterns. Indonesia, China and Cambodia remained among the Group's key international source markets.

At the Group level, EBITDA growth continued to outpace revenue growth as higher hospital activities and improved utilisation supported better operating leverage. Profit before tax increased 54% y-o-y to RM121.3 million, with stronger operating earnings and lower net finance costs more than offsetting higher depreciation and amortisation expenses associated with the Group's recent capacity expansion.

Operational and Strategic Developments

The Group achieved a significant operational milestone with the opening of SMC Sunway City's new 216-bed-capacity Children's Tower, Tower F, in August 2026. Of these, 108 beds were licensed during Q3FY2026, with the remaining beds to be progressively licensed and operationalised, strengthening the flagship hospital's dedicated paediatric infrastructure and specialised clinical capabilities. Tower F further strengthens SMC Sunway City’s comprehensive paediatric care offering through its specialised

inpatient wards, complementing the hospital's existing dedicated Children's Emergency Department, purpose-built paediatric intensive care facilities, and multidisciplinary expertise spanning 28 paediatric sub-specialties.

Complementing this capacity expansion, SMC Sunway City secured the No. 1 position in Malaysia in Newsweek's *World's Best Smart Hospitals 2027* ranking, alongside No. 1 ranking in Malaysia for Paediatrics and Neurology, as well as No. 2 for Oncology, in Newsweek's *World's Best Specialized Hospitals 2027* rankings. Separately, SMC Penang earned recognition in the Ophthalmology and Orthopaedics categories of Newsweek's *World's Best Hospitals & Clinics for Medical Tourism 2027*. These accolades underscore the Group's continued investment in clinical excellence, specialist and nursing capabilities, and advanced medical infrastructure across its hospital network.

Meanwhile, expansion works for Phase 3 of SMC Penang commenced during the quarter, with the development expected to add 105 beds by the second half of 2028, further strengthening the Group's capacity to serve growing healthcare demand in the northern region, particularly for cancer cases. Together with other brownfield expansion initiatives, this supports the Group's target of approximately 2,400 hospital beds by 2028. Separately, renovation works for an additional 256 guest rooms at Sunway Sanctuary also commenced in Q3FY2026, with completion targeted for Q4FY2027, supporting the Group's expansion of its senior living offerings.

The Group also made tangible progress in its next phase of greenfield hospital developments. The groundbreaking of SMC Iskandar Puteri in Johor took place in September 2026, marking an important step towards establishing the Group's presence in the southern region. During the same month, the Group executed the land acquisition agreement for its planned hospital in Seremban Sentral, Negeri Sembilan. Subsequently, in October 2026, the Group formalised its joint venture arrangements with Putrajaya Holdings Sdn Bhd for the development of SMC Putrajaya.

These developments form part of the Group's longer-term strategy to broaden access to quality private healthcare across Malaysia, with the combined capacity of its hospital network expected to exceed 3,400 beds by 2032, subject to the relevant approvals and prevailing project timelines.

Outlook

The Group remains positive about its prospects for FY2026 and beyond, underpinned by favourable long-term healthcare demand fundamentals, its expanding clinical capabilities and the progressive maturation of its hospital network. The sustained improvement in patient activities and operating profitability through 9MFY2026 provides a solid foundation for continued growth, with further opportunities arising from higher capacity utilisation and the expanding contributions of its newer hospitals.

Dato' Lau Beng Long, President of Sunway Healthcare Group said, "Our latest result demonstrates that the capacity we have added is progressively translating into stronger patient activity and earnings. Importantly, occupancy improved despite the significant increase in licensed beds, while our newer hospitals continued to strengthen their contribution to the Group. As we activate the remaining capacity across our network, our priorities are clear: to drive sustainable utilisation, deepen our specialist capabilities, improve operating productivity and maintain disciplined capital deployment. This will allow us to continue delivering quality care while creating sustainable long-term value."

As at 30 September 2026, the Group had 1,994 licensed beds and a further 277 completed beds available for licensing, bringing total capacity to 2,271 beds. The Group will continue to progressively license and operationalise its remaining capacity, particularly at SMC Sunway City's Tower F, SMC Damansara and SMC Ipoh, supported by specialist recruitment and service expansion. In parallel, brownfield development programmes at SMC Damansara and SMC Penang, together with ongoing greenfield and Ambulatory Care Centre initiatives, are expected to provide additional capacity to support the Group's medium- and longer-term growth.

The evolving healthcare-financing landscape, including MediAsas and the progressive implementation of DRG-based reimbursement, is expected to increase focus on affordability, transparency and sustainable healthcare costs. The Group will continue to engage constructively with insurers, takaful operators and relevant stakeholders, while protecting margins through disciplined pricing and discount governance, procurement initiatives, clinical cost management and continued improvements in operating productivity.

Medical tourism remains an important growth opportunity, supported by Malaysia's established position as a regional healthcare destination. The Group will continue to broaden its international patient source markets, deepen referral and insurer partnerships, and strengthen higher-value specialist offerings, while remaining mindful of geopolitical developments and regional travel uncertainties.

With its established hospital network, growing specialist capabilities and expanding capacity, the Group will remain focused on converting patient-volume growth and progressive capacity activation into sustainable earnings, while maintaining clinical excellence, operational resilience and financial discipline.

(Notes: 1. The financial results for Q3FY2026 and 9MFY2026 presented therein are unaudited. 2. Normalised EBITDA is a non-MFRS financial measure and is presented to provide additional insight into the Group's underlying operating performance. It is not a substitute for EBITDA or profit measures prepared under MFRS)

***

Press Release

For Immediate Distribution

For media enquiries, please contact:

Puteri Farhana (Farah): puteriffmi@sunway.com.my, +6012-777 6049

Sarah Chew: sarahcsm@sunway.com.my, +6016-225 9991

For investor relations, please contact:

Victor Geh: victorgck@sunway.com.my, +6016-421 1008

About Sunway Healthcare Holdings Berhad

Sunway Healthcare Holdings (SHH), through its subsidiaries, is one of the leading integrated private healthcare providers with an extensive network of hospitals and healthcare services in Malaysia.

SHH's network includes its flagship quaternary hospital Sunway Medical Centre in Sunway City Kuala Lumpur, tertiary hospitals Sunway Medical Centre Velocity, Sunway Medical Centre Penang, Sunway Medical Centre Damansara, and Sunway Medical Centre Ipoh, ambulatory care centres at Sunway Specialist Centre Damansara and Sunway Fertility Centre (Kuching and Kota Bharu) and supportive and complementary care centres at Sunway TCM Centre and Sunway Home Healthcare. SHH also operates Sunway Sanctuary, an integrated senior living facility annexed to Sunway Medical Centre Sunway City Kuala Lumpur.

At the heart of SHH are skilled and experienced healthcare professionals, supported by some of the most advanced medical equipment available today, attracting international patients from all over the world.

With the aim to shape the future of healthcare, SHG has strategic collaborations in the domains of medical training, education, and clinical research with internationally renowned institutions such as the University of Cambridge, Royal College of Physicians, and Harvard Medical School.

As part of its expansion strategy to provide more communities with access to quality healthcare, SHH will increase its footprint across Malaysia with tertiary hospitals in Seremban (Negeri Sembilan), Putrajaya, and Iskandar Puteri (Johor). With this growth, SHH expects to have a combined capacity of over 3,400 beds among its network of hospitals by 2032.

To learn more, visit https://www.sunwayhealthcaregroup.com/

Issued by: Sunway Healthcare Holdings Berhad

Date: 19 November 2026